Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Pharmacological characterization of the orexin/hypocretin receptor agonist Nag 26.

Rinne MK, Leino TO, Turku A, Turunen PM, Steynen Y, Xhaard H, Wallén EAA, Kukkonen JP.

Eur J Pharmacol. 2018 Oct 15;837:137-144. doi: 10.1016/j.ejphar.2018.09.003. Epub 2018 Sep 5.

PMID:
30194937
2.

Stapled truncated orexin peptides as orexin receptor agonists.

Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA.

Peptides. 2018 Apr;102:54-60. doi: 10.1016/j.peptides.2018.02.004. Epub 2018 Feb 21.

3.

Endocannabinoid Signaling in Embryonic Neuronal Motility and Cell-Cell Contact - Role of mGluR5 and TRPC3 Channels.

Turunen PM, Louhivuori LM, Louhivuori V, Kukkonen JP, Åkerman KE.

Neuroscience. 2018 Apr 1;375:135-148. doi: 10.1016/j.neuroscience.2018.02.005. Epub 2018 Feb 10.

PMID:
29438802
4.

Regulation of radial glial process growth by glutamate via mGluR5/TRPC3 and neuregulin/ErbB4.

Louhivuori LM, Turunen PM, Louhivuori V, Yellapragada V, Nordström T, Uhlén P, Åkerman KE.

Glia. 2018 Jan;66(1):94-107. doi: 10.1002/glia.23230. Epub 2017 Sep 9.

PMID:
28887860
5.

Calpain Activity Is Essential for ATP-Driven Unconventional Vesicle-Mediated Protein Secretion and Inflammasome Activation in Human Macrophages.

Välimäki E, Cypryk W, Virkanen J, Nurmi K, Turunen PM, Eklund KK, Åkerman KE, Nyman TA, Matikainen S.

J Immunol. 2016 Oct 15;197(8):3315-3325. Epub 2016 Sep 16.

6.

Transient receptor potential channels and their role in modulating radial glial-neuronal interaction: a signaling pathway involving mGluR5.

Louhivuori LM, Jansson L, Turunen PM, Jäntti MH, Nordström T, Louhivuori V, Åkerman KE.

Stem Cells Dev. 2015 Mar 15;24(6):701-13. doi: 10.1089/scd.2014.0209. Epub 2014 Dec 17.

7.

Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling.

Jäntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Lindqvist C, Kukkonen JP.

Mol Pharmacol. 2013 Mar;83(3):621-32. doi: 10.1124/mol.112.080523. Epub 2012 Dec 11.

PMID:
23233488
8.

OX1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release.

Turunen PM, Jäntti MH, Kukkonen JP.

Mol Pharmacol. 2012 Aug;82(2):156-67. doi: 10.1124/mol.112.078063. Epub 2012 May 1.

PMID:
22550093
9.

Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction.

Putula J, Turunen PM, Johansson L, Näsman J, Ra R, Korhonen L, Kukkonen JP.

FEBS Lett. 2011 May 6;585(9):1368-74. doi: 10.1016/j.febslet.2011.04.020. Epub 2011 Apr 15.

10.

Agonist ligand discrimination by the two orexin receptors depends on the expression system.

Putula J, Turunen PM, Jäntti MH, Ekholm ME, Kukkonen JP.

Neurosci Lett. 2011 Apr 20;494(1):57-60. doi: 10.1016/j.neulet.2011.02.055. Epub 2011 Mar 6.

PMID:
21362456
11.

Filtration assay for arachidonic acid release.

Turunen PM, Putula J, Kukkonen JP.

Anal Biochem. 2010 Dec 15;407(2):233-6. doi: 10.1016/j.ab.2010.07.014. Epub 2010 Jul 23.

PMID:
20655865
12.

Arachidonic acid release mediated by OX1 orexin receptors.

Turunen PM, Ekholm ME, Somerharju P, Kukkonen JP.

Br J Pharmacol. 2010 Jan;159(1):212-21. doi: 10.1111/j.1476-5381.2009.00535.x. Epub 2009 Dec 4.

13.

Involvement of TRPC3 channels in calcium oscillations mediated by OX(1) orexin receptors.

Peltonen HM, Magga JM, Bart G, Turunen PM, Antikainen MS, Kukkonen JP, Akerman KE.

Biochem Biophys Res Commun. 2009 Jul 31;385(3):408-12. doi: 10.1016/j.bbrc.2009.05.077. Epub 2009 May 21.

PMID:
19464259

Supplemental Content

Loading ...
Support Center